SMSarah Mrejen

Sarah Mrejen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Mrejen has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PIGMENT EPITHELIUM DETACHMENT IN SEVERE ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY

    by Alexandre Dentel, Chloé Widehen, Paul Goupillou, Florence Hoogewoud, Sarah Mrejen, Christine Fardeau, Cherif Titah, Mohamed A. Gargouri, Aude Couturier, Alain Gaudric, et al.

    Purpose: To describe the spectrum of optical coherence tomography (OCT) findings in acute posterior multifocal placoid pigment epitheliopathy (APMPPE), with a specific focus on the prevalence of pigment epithelium detachments (PEDs). Methods: Multicenter, retrospective, longitudinal study including patients diagnosed with APMPPE based on color fundus photography, OCT, and fluorescein angiography. Demographics, visual acuity, and the following OCT findings were assessed: outer retinal hyperreflectivity, serous retinal detachment (SRD), bacillary layer detachment (BALAD), and PED. Results: Forty-six eyes of 27 patients were included. The median age at presentation was 23 years (range: 18–36 years), and 17 patients (62.9%) were men. At baseline, outer retinal hyperreflectivity was found in all eyes, while BALAD, SRD, and PED were observed in 22 (47.8%), 14 (30.4%), and 26 eyes (56.5%), respectively. A univariate logistic regression showed a significant association between the presence of PED and a worse baseline visual acuity (odds ratio [OR]: 5.3; 95% confidence interval [CI]: 1.5–18.6; P = 0.01), the presence of BALAD (OR: 9.0; 95% CI: 2.3–35.6; P = 0.002), and the presence of SRD (OR: 7.3; 95% CI: 1.4–38.3; P = 0.02). Conclusion: PEDs were significantly associated with a poorer initial visual acuity, as well as with the presence of BALAD and SRD on presentation. These findings suggest that PEDs could be used as a biomarker of disease severity and choriocapillaris ischemia in APMPPE.

  • Open Access

    Multimodal Imaging of Unilateral Acute Maculopathy Associated with Hand, Foot, and Mouth Disease: A Case Series

    by Mickael Anjou, Franck Fajnkuchen, Nicolas Nabholz, Sylvia Nghiem-Buffet, Sarah Mrejen, Audrey Giocanti-Aurégan

    We described clinical and multimodal imaging findings in 4 patients with unilateral acute idiopathic maculopathy (UAIM) associated with hand, foot, and mouth disease. Four eyes of 4 patients (3 women and 1 man) with a mean age of 35 years (range: 24–40 years) were included. A bacillary detachment was observed in 3 out of the 4 eyes and was strongly suspected in the remaining eye. This particular detachment was resolved within 5–10 days in our series. A choriocapillaris involvement was supported by the multimodal imaging findings. On indocyanine green angiography, a hypofluorescence was observed throughout the sequence, and OCT angiography showed a defect of the choriocapillaris perfusion. In this case series, a complete multimodal retinal assessment allowed identifying the choriocapillaris as the primary tissue involved in UAIM associated with coxsackie virus infection. In 3 out of our 4 cases, a bacillary detachment with a transient evolution was identified.


  • Open Access

    Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis

    by Frédéric Matonti, Jean-François Korobelnik, Corinne Dot, Vincent Gualino, Vincent Soler, Sarah Mrejen, Marie-Noëlle Delyfer, Stéphanie Baillif, Maté Streho, Pierre Gascon, et al.

    Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) have become the standard of care for age-related macular degeneration (AMD). Although most pivotal trials have used monthly injections, alternative strategies that enable the injections to be administered on a more flexible schedule, including pro re nata (PRN) and treat-and-extend (T&E) regimens, are being applied more frequently. This review sought to provide further scientific evidence about the visual outcomes and treatment burden among the currently available anti-VEGF agents and regimens, including aflibercept, ranibizumab, abicipar and brolucizumab. To this end, a systematic review of published randomized studies was conducted from the MEDLINE and EMBASE databases and the Cochrane library, and a meta-analysis was applied to the obtained data using single-means modeling to compare the efficacy and maintenance among the different available treatments and regimens at Years 1 and 2. Quality analysis identified the best-informed data for modeling purposes. Overall, 47 relevant publications were retrieved for the analysis. Superior efficacy, meaning that there were observed improvements in visual acuity (VA) and central retinal thickness (CRT), occurred with monthly versus PRN regimens, yet a higher IVI number was also observed. Conversely, the T&E regimens displayed similar efficacy to the monthly regimens, but with a reduced IVI number. Aflibercept T&E exhibited similar efficacy to ranibizumab T&E, but with significantly lower IVI numbers at both Year 1 (p < 0.0001) and Year 2 (p = 0.0011). Though all of the regimens resulted in maintained efficacy between Years 1 and 2, the required IVI number varied. The retrieved data did not enable other regimens or newer anti-VEGF agents such as brolucizumab to be compared. In conclusion, the T&E regimens were shown to be the most efficient, optimizing durable effectiveness whilst minimizing the IVI number in newly diagnosed exudative AMD, with aflibercept requiring the lowest IVI number.


  • Top Cited Papers

    Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy

    by Sarah Mrejen, Chandrakumar Balaratnasingam, Talia R. Kaden, Alexander Bottini, Kunal Dansingani, Kavita V. Bhavsar, Nicolas A. Yannuzzi, Samir Patel, Kevin C. Chen, Suqin Yu, et al.


  • Open Access

    Clinical course of acute zonal occult outer retinopathy complicated by choroidal neovascularization

    by Ugo Introini, Giuseppe Casalino, Elona Dhrami-Gavazi, Sri Krishna Mukkamala, Sarah Mrejen, Hermann Schubert, Salomon Y. Cohen, Claudio Azzolini, Francesco Bandello, Stanley Chang, et al.

    To report the clinical course and multimodal imaging features of acute zonal occult outer retinopathy (AZOOR) complicated by choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factor (VEGF) treatment or photodynamic therapy (PDT). Observational case series. Retrospective analysis of patients presenting to different institutions with evidence of AZOOR and neovascular lesions. Diagnosis of AZOOR was made on the basis of clinical presentation and multimodal imaging. All patients underwent a comprehensive ophthalmic evaluation and multimodal retinal imaging, including color fundus photos, fundus autofluorescence, fundus fluorescein angiography and spectral-domain optical coherence tomography. Four patients (three males, mean age 53.5 years) were included in the study. Mean follow-up was 5.1 years. Presentation of AZOOR was unilateral in two patients and bilateral in the remainder two patients. One of the patients presenting with unilateral AZOOR developed zonal lesions in the fellow eye during follow-up. All patients presented with unilateral type 2 (subretinal) CNV. Three patients underwent intravitreal anti-VEGF injections and one patient underwent a single PDT. Multimodal retinal imaging showed zonal or multizonal progression during treatment. After treatment, visual acuity and CNV stabilization was observed in all patients. The presence of CNV expands the clinical spectrum of AZOOR. CNV complicating AZOOR may be effectively treated with intravitreal injections of anti-VEGF, despite progression of the zonal lesions. Further studies are required to define the role of treatment in the progression of the zonal lesions.


  • Open Access

    Atypical retinal pigment epithelial defects with retained photoreceptor layers: a so far disregarded finding in age related macular degeneration

    by Helena Giannakaki-Zimmermann, Giuseppe Querques, Inger Christine Munch, Daraius Shroff, David Sarraf, Xuejing Chen, Eduardo Cunha-Souza, Sarah Mrejen, Vittorio Capuano, Murilo W. Rodrigues, et al.

    To report patients with age-related macular degeneration and atypical central retinal pigment epithelium (RPE) defects not attributable to geographic atrophy (GA) or RPE-tears with overlying preserved photoreceptor layers. Multimodal imaging case-series evaluating the course of atypical RPE- defects in patients with AMD using Color fundus images, Optical coherence tomography (OCT), OCT-Angiography, fundus autofluorescence (FAF) and fluorescein-angiography (FA). Ten patients were identified. Three patients had a prior RPE-rip and were excluded. Seven patients with a mean follow-up period of 47 ± 38 months after the occurrence of the RPE-defect were included (age range 71–87 years). Mean distance Best corrected visual acuity (BCVA) at initial presentation was 0.36 ± 0.29logMAR and at last follow-up visit 0.51 ± 0.43logMAR. Patients presented with clinically apparent GA on funduscopy and FAF, but preserved photoreceptor layers on optical coherence tomography (OCT). On FA there was early hyperfluorescence and late pooling visible. Over time, migration of RPE/drusenoid material right above the Bruch’s membrane with concomitant decrease of hypoautofluorescence was detectable in 4 cases. An enlargement of the RPE-defect was apparent in the remaining 3 cases. The majority (n = 4) showed a drusenoid pigment epithelium detachment (PED) preceding the lesion. Beside GA and characteristic RPE-tears, another atypical form of RPE-defect with overlying preserved photoreceptor layers are found in AMD. This so far disregarded subgroup of patients present with reasonable visual function and long-term survival of photoreceptors layers. Repair mechanisms such as ingrowth of RPE/drusenoid material and persistent subretinal fluid (SRF), but also a RPE-independent visual cycle for cone photopigment within the neurosensory retina may contribute to their favorable course.


  • Open Access

    Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration

    by Sarah Mrejen, Jesse J. Jung, Christine Chen, Samir N. Patel, Roberto Gallego-Pinazo, Nicolas Yannuzzi, Luna Xu, Marcela Marsiglia, Sucharita Boddu, K. Bailey Freund

    With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with treatment-naïve NVAMD initially classified based on fluorescein angiography (FA) alone or with an anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed over an average of 3.5 years (range 1–6.6) with a retention rate of 62.9%, and visual acuity significantly improved with a TER that required a mean number of 8.3 (±1.6) (± standard deviation) intravitreal anti-VEGF injections/year (range 4–13). The number of injections and the anatomic classification were independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1 neovascularization had better visual outcomes and received more injections than the other neovascular subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes.


  • Peripheral Retinal Abnormalities

    by Sarah Mrejen, Michael Engelbert